IDH is one of the most studied genes in glioma development, and cancers with IDH1 or IDH2 mutations produce 10–100 times more 2-HG than those with the IDH1 or IDH2 wildtype (Ward et al. 2010; Leeper et al. 2015). This evidence concerns the gene IDH1 and central nervous system cancer.